Last reviewed · How we verify

NCT03606915

Investigating the Role of Brain-derived Neurotrophic Factor (BDNF) Between Pain and Other Neuronal Disease

Completed Last updated 26 February 2020
What this trial tests

trial testing pain evaluation in Pain in 131 participants. Completed in 31 December 2019.

Timeline
10 July 2015
Primary endpoint
31 December 2019
31 December 2019

Quick facts

Lead sponsorNational Cheng-Kung University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment131
Start date10 July 2015
Primary completion31 December 2019
Estimated completion31 December 2019
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Cheng-Kung University Hospital

Who can join

Adults 20 to 90, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Measure the cytokines, transforming or neurotrophic factors in CSF and plasma as the pain markers and as a new therapeutic target for pain control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. TGF-β1 in plasma and cerebrospinal fluid can be used as a biological indicator of chronic pain in patients with osteoarthritis.
    Liu YC, Hsiao HT, Wang JC, Wen TC, et al · · 2022 · cited 10× · PMID 35061744 · DOI 10.1371/journal.pone.0262074

Verify or expand the search:

Other trials of pain evaluation

Trials testing the same drug.

Other recruiting trials for Pain

Currently open trials in the same condition.

Other National Cheng-Kung University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03606915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing